Restore Mind Medicine

References [1] The SPDR S&P Biotech ETF presents the performance of a broad spectrum of biotechnology companies. The remaining comparable companies represent the holdings of Horizons Psychedelic Stock Index ETF excluding Johnson & Johnson, Abbvie Inc, and FSD Pharma Inc. Johnson & Johnson and Abbvie Inc. were excluded due to their significant exposure to other drugs and products. FSD Pharma Inc. was excluded as it has pivoted its strategic aims significantly over the timeframe. [2] The relative performance of x with respect to y is the ratio between r_u and r_y minus one. [3] See Freeman et al. v. Hurst et al. United States District Court, District of Nevada. See Barrow's interview with Psychedelic Invest dated October 7, 2022. See MindMed's MMED-003 Protocol V2. [4] See [5] Based on Robert Barrow and Danial Karlin's LinkedIn dated May 4, 2023. [6] These estimates are based on public data, industry trends, and experience. The Board will review and revise as needed should our slate be elected. [7] Based on the imputed value of issued warrants on the date of close (September 30, 2022) as calculated in MindMed's 10-Q dated November 10, 2022. [8] Based on direct ownership of Common Shares and does not include derivative exposure. The peer group is based on the same peer group in FCM's Definitive Proxy Statement. Based on EDGAR and SEDAR filings and includes certain shares held in a family trust for Michael Forer, see ATAI Proxy Statement 2023 Footnote 1 Page 31 (aggregated to 23,364,432 for Christian Angermayer), and including certain shares owned by M3 Daat LLC, of which Michael Auerbach is a member. [9] Based on the estimates of Oppenheimer (May 4, 2023), Roth Capital Partners (April 14, 2023), RBC (May 4, 2023), Maxim Group (May 5, 2023), Cantor Fitzgerald (May 7, 2023), and HC Wainwright (May 9, 2023). EF Hutton and Canaccord Genuity were not included as neither has published both 2023 and 2024 estimates since April 2023. When cash flow estimates were not provided, net loss was translated to cash flow change by using the ratio of net cash used in operating activities to net income in MindMed's 10-K for FY2022. [10] Based on FCM's review of the relevant board members LinkedIn. [11] Based on FDA drug approvals from 2012 to April 2023 for new molecules. The full data set is available ats https://mindmed.zone/clinical-trial-data which describes the various drugs classified as CNS drugs. Phase Ilb is not a technically defined term; however, the analysis utilized the following criterion for classifying a trial as a Phase Ilb: (1) the trial was a Phase II or Phase I/II per the trial's description on Clinical Trials.gov, (2) the trial either described itself as a Phase IIb, a dose finding study, dose optimization study, or had more than three unique dosing schedules tested across its experimental arms (one dosing schedule per arm), (3) it had a primary endpoint that was not a biomarker, and (4) the primary completion of the study occurred prior to the application of new drug approval. For avoidance of doubt, a Phase II/III study is not classified as a Phase II or Phase IIb study. Phase lla studies were not counted as completing Phase II. Additionally, the Phase II study had to be in an indication related to the approved indication as well as had the primary completion date before the submission of the new drug application to the FDA. See Pfizer and Zavzpret, AbbVie and Qulipta (note that although AbbVie describes one of its Phase III trials as a Phase IIb/III trial in its press releases, in its filings the FDA it is described as a Phase III), Amgen and Aimovig. See FDA Guideline for Industry: Dose-Response Information to Support Drug Registration. Major market mental health drugs were CNS drugs (see supra at 1) that treated the following symptoms: depression, insomnia, schizophrenia, addiction, migraine, and attention deficit hyperactivity disorder. [12] See PAR-22-142, NINDS 2022 Congressional Budget Justification. [13] Exchange rate from Canadian dollars to USD was from XE.com for February 18, 2021. MindMed's 10-K for FY 2022. Based on a comparison of MindMed's digital medicine candidates as described in MindMed's Investor Presentations for February 2021 and March 2023. [14] See Canaccord Genuity research notes dated September 28, 2022 and October 10, 2022. [15] Based on MindMed's balance sheet on September 30, 2022 (the same day the September Financing closed) adjusted for the September Financing. The cash per share would be slightly higher as it does not account for cash burn between September 27, 2022 and September 30, 2022. Data from MindMed's 10-Q for Q3 of 2022. [16] See CVI Investment's 13G reporting for September 27, 2022. CVI Investment's 13-F for Q1 2023 and CVI Investment's 13-F dated for September 30, 2022. See 13-F Filings in MindMed. [17] See MindMed's Audited Financial Statements for FY2020; core dru R&D spending defined to be the manufacturing costs, clinical research & regulatory expenses, and data & study acquisition costs - these costs were incurred in direct support of the MM-110 clinical trial and to advance the MM-120 program including through the UHB collaboration data acquisition. [18] Based on FCM's review of LinkedIn profiles for MindMed employees where FCM found three employees engaged in human resources functions. See SHRM 2017 Report HUMAN CAPITAL BENCHMARKING REPORT [19] See [8] [20] On May 19, 2023, FCM conducted a review of each employee listed of MindMed's LinkedIn page as working for the Company. Based on the job description, FCM made classifications for employees. Although we attempted to remove employees who seemed elsewhere employed it is likely that this review does not fully account for employees who have left nor employees who have joined but updated their respective LinkedIn. [21] See Compass Pathway, Matthew South Convertible Database 95

View entire presentation